RXRX Stock Risk & Deep Value Analysis
Recursion Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About RXRX Stock
We analyzed Recursion Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran RXRX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is RXRX Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for RXRX?
- ⚠
Negative or inconclusive clinical trial results for lead candidates
- ⚠
Higher-than-expected cash burn impacting runway, necessitating dilutive fundraising
- ⚠
Intensified competition from other AI drug discovery firms or large pharma's in-house efforts
- ⚠
Unexpected regulatory delays or challenges in drug approval process
Unlock RXRX Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Recursion Pharmaceuticals Inc (RXRX) Do?
Market Cap
$2.30B
Sector
Healthcare
Industry
Biotechnology
Employees
800
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Visit Recursion Pharmaceuticals Inc WebsiteIs RXRX Stock Undervalued?
Unlock the full AI analysis for RXRX
Get the complete DVR score, risk analysis, and more
Does RXRX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is primarily built on proprietary algorithms, unique biological datasets, and the integrated automation of its biofoundry, which creates a flywheel effect of data generation and model refinement. This cumulative advantage is difficult and capital-intensive for competitors to replicate.
Moat Erosion Risks
- •Emergence of superior AI models or platforms from well-funded competitors
- •Large pharmaceutical companies developing robust in-house AI capabilities
- •Regulatory changes impacting data privacy or drug discovery processes
RXRX Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive RXRX Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated late April/early May 2026)
- •Updates on early-stage clinical trial progress (Phase 1/2 data presentation)
- •New strategic platform enhancements or technology integrations
Medium-Term (6-18 months)
- •Announcement of additional pharmaceutical partnerships
- •Advancement of lead drug candidates into later-stage clinical trials (Phase 2 readouts)
- •Expansion of drug pipeline candidates and therapeutic areas
Long-Term (18+ months)
- •Successful regulatory approval and commercialization of first AI-discovered drug
- •Establishment as a dominant 'Biofoundry' for drug discovery and development
- •Industry-wide shift towards AI-driven drug development, with RXRX as a leader
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for RXRX?
- ✓
Positive clinical trial data readouts (especially progression into Phase 2/3)
- ✓
Announcements of new large-scale pharmaceutical partnerships or collaborations
- ✓
Demonstrated improvements in cash runway and reduced burn rate
- ✓
Successful expansion of drug pipeline beyond current lead candidates
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for RXRX (Recursion Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
